Bridgepoint Group (BPT) Trading update summary
Event summary combining transcript, slides, and related documents.
Trading update summary
27 Oct, 2026Performance and guidance
FY2026 PRE expected at 37%-39% of total income; medium-term PRE guidance from 2027 raised to 25%-30%; EBITDA margin guidance ~60% in 2026/27.
EBITDA guidance upgraded on exceptional ECP V performance; its gross MOIC exceeded 3x at June and is expected to exceed 4x at Q3, including a material ProEnergy valuation increase.
If ProEnergy remains at its Q3 valuation, 2026 PRE is expected to rise by ~$185m versus current consensus; further valuation upside could lift the outlook.
Management fee growth guidance is 13%-16% on a rolling three-year basis; expenses expected to rise at a high-single-digit rate in 2026 and mid-single-digit rates from 2027.
Cash generation and shareholder distributions
Projected 2026-30 cash receipts total £2.4bn: £1.3bn from PRE and £1.1bn from co-investments, versus ~£500m in 2021-25.
From FY2027, ordinary dividends target 40%-45% of EPS and will be paid quarterly.
Total capital returns target 40%-60% of Cash from Profits over five years to 2030, using ordinary dividends and additional dividends or buybacks as appropriate.
FY2026 dividend per share rebased from ~10p to 15p, subject to shareholder approval.
Transition dividends comprise a 4.8p interim, 5p Q3 second interim payable November 12, and intended 5.2p final dividend, subject to approval.
Fundraising and transactions
The €28bn mid-2024–2026 fundraising target was reached early; more than €30bn expected by year-end 2026, including €16bn raised in 2026; over a third of new flagship-fund capital came from new investors.
BE VIII raised €7.8bn, is expected to reach its €8.65bn hard cap and be fully allocated later in 2026, and has been fee-paying since June 9, 2026.
ECP VI closed at $8.1bn; BDL IV closed at €5.1bn, up 76% from BDL III; CLO X and XI priced successfully and CLO I reset.
KARE shareholder and fund-investor approvals received; completion expected January 4, 2027. Post-Kayne AUM expected at ~$125bn, with ~50% in the U.S. and ~50% in real assets.
Deployment: BE VIII 13%, BDC 49%, ECP VI 25% and KAREP VII 54%; up to 17 funds may be in market next year.
Latest events from Bridgepoint Group
- EBITDA up 78%, AUM up 38%, and fundraising nears €28bn with US expansion via Kayne Anderson.BPT
H1 2026 - Acquisition of KARE for $1.393bn boosts AUM to $117bn and accelerates earnings growth.BPT
M&A announcement - AUM up 24% to $94.1bn, EBITDA margin at 53%, and fundraising momentum remains strong.BPT
H2 2025 - AUM up 20% year-over-year, €2.6bn returned to investors, and fundraising advanced.BPT
H1 2025 - Targeting $200bn AUM in 5–6 years, driven by scaling, M&A, and product innovation.BPT
CMD 2024 - H1 2024 saw record fundraising, strong earnings growth, and upgraded guidance.BPT
H1 2024 - EBITDA up 96%, AUM up 80% to $75.6bn, and fundraising target raised to €24bn.BPT
H2 2024